XPC gene variants: A risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 5, 2010, Pages 779-786

  Gangwar, Ruchika ^a   Mandhani, Anil ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bacillus calmette guerin; Bladder cancer; DNA repair; Polymorphism; Recurrence; XPC

Indexed keywords

BCG VACCINE; GLUTAMINE; LYSINE; XERODERMA PIGMENTOSUM GROUP C PROTEIN; DNA BINDING PROTEIN; XPC PROTEIN, HUMAN;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GENE DELETION; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; BLADDER TUMOR; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; ONSET AGE; TRANSITIONAL CELL CARCINOMA;

AGE OF ONSET; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 77950505332     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0717-y     Document Type: Article

References (30)

1. Berwick M, Vineis P (2000) Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92:874-897
2. Blankenburg S, Konig IR, Moessner R et al (2005) Assessment of 3 xeroderma pigmentosum groupC gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis 26:1085-1090 (Pubitemid 41214301)
3. Casson AG, Zheng Z, Evans SC et al (2005) Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis 26:1536-1541
4. Chopin DK, Gattegno B (2002) Superficial bladder tumors. Eur Urol 42:533-541
5. Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921-927
6. Fontana L, Bosviel R, Delort L et al (2008) DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res 28:1853-1856 (Pubitemid 351892896)
7. Garcia-Closas M, Malats N, Real FX et al (2006) Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 15:536-542
8. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
9. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366-374
10. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics. CA Cancer J Clin 54:8-29
11. Larsson P, Wijkstrom H, Thorstenson A et al (2003) A populationbased study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 37:195-201
12. Legerski R, Peterson C (1992) Expression cloning of a human DNA repair gene involved in xeroderma pigmentosum group C. Nature 359:70-73
13. Li L, Peterson C, Legerski R (1996) Sequence of the mouse XPC cDNA and genomic structure of the human XPC gene. Nucleic Acids Res 24:1026-1028
14. López-Cima MF, González-Arriaga P, García-Castro L et al (2007) Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of Northern Spain. BMC Cancer 7:162-173
15. Lynch CF, Lohen MB (1995) Urinary system. Cancer 75:316-329
16. Merz VW, Marth D, Kraft R et al (1995) Analysis of early failures after intravesical instillation therapy with Bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 75:180-184
17. Messing EM, Young TB, Hunt VB et al (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45:396-397
18. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
19. Pashos CL, Botteman MF, Laskin BL et al (2002) Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 10:311-322
20. Qiao Y, Spitz MR, Guo Z et al (2002) Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 509:165-174
21. Sak SC, Barrett JH, Paul AB et al (2005) The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder. Br J Cancer 92:2262-2265
22. Sands AT, Abuin A, Sanchez A et al (1995) High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377:162-165
23. Schenk-Braat EA, Bangma CH (2005) Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother 54:414-423
24. Shen H, Sturgis EM, Khan SG et al (2001) An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res 61:3321-3325
25. Sobin LH, Wittekind Ch (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York, pp 199-202
26. Sugasawa K, Ng JM, Masutani C et al (1998) Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell 2:223-232
27. van Hoffen A, Balajee AS, van Zeeland AA et al (2003) Nucleotide excision repair and its interplay with transcription. Toxicology 193:79-90
28. Wood RD, Mitchell M, Sgouros J et al (2001) Human DNA repair genes. Science 291:1284-1289
29. Zhang L, Zhang Z, Yan W (2005) Single nucleotide polymorphisms for DNA repair genes in breast cancer patients. Clin Chim Acta 359:150-155
30. Zhang D, Chen C, Fu X et al (2008) A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. J Hum Genet 53:18-33